Prosecution Activities Sample Clauses

The Prosecution Activities clause defines the responsibilities and procedures related to the filing, management, and maintenance of intellectual property rights, such as patents or trademarks. Typically, this clause outlines which party is responsible for preparing and submitting applications, responding to office actions, and covering associated costs. It may also specify how decisions are made regarding the scope or jurisdiction of filings. The core function of this clause is to ensure clear allocation of duties and costs in protecting intellectual property, thereby preventing disputes and ensuring that valuable rights are properly secured and maintained.
Prosecution Activities. With respect to the Ambit Licensed Patents and the Program Patents, the Party with the first right to control Prosecution of Patent Rights as set forth in Section 8.3.1(a) through (c) (the “Lead Prosecuting Party”) shall direct and control the Prosecution of such Patent Rights, including the preparation, filing and prosecution of all U.S. and foreign patent applications within such Patent Rights, and the conduct of any interferences, reexaminations, reissues and foreign oppositions relating to such Patent Rights (as further discussed in Section 8.3.7 below).
View SourceView Similar (4)
Prosecution Activities. Juniper shall promptly inform ▇▇. ▇▇▇▇▇▇▇▇ of any activities in connection with any reexamination, reissuance or extension of any Assigned Patent (“Prosecution Activities”). ▇▇. ▇▇▇▇▇▇▇▇ may recommend courses of action in connection with such Prosecution Activities and Juniper shall consider in good faith such recommendations. ▇▇. ▇▇▇▇▇▇▇▇ shall cooperate with Juniper with respect to such Prosecution Activities, including without limitation: (i) being reasonably available to Juniper (or Juniper’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable Juniper to undertake Prosecution Activities; (ii) providing Juniper with copies of all correspondence pertaining to the Assigned Patents, to the extent not provided to Juniper as part of the Patent Files under Section 2.3 hereof; and (iii) cooperating, if necessary and appropriate, with Juniper in gaining patent term extensions whenever applicable.
View SourceView Similar (2)
Prosecution Activities. As between the Parties, Syros shall have the sole right to be the Prosecuting Party for the Non-Validated Target Patents, worldwide, at Incyte’s sole cost and expense and using counsel mutually agreed upon by the Parties. Unless otherwise agreed by the Parties in writing, and subject to Incyte fulfilling its obligations with respect to such costs and expenses, Syros shall not abandon any Non-Validated Target Patent that Covers any Know-How relating to any Definitive Research Target during the period that Incyte retains an unexercised Option to select such Definitive Research Target as a Validated Target.
View Source
Prosecution Activities. (i) Subject to Section 9.3(b)(ii), AGIX shall control Prosecution of all Licensed Patents and Joint Patents, under the direction of the IPC. AstraZeneca shall have the right to comment on Prosecution activities by AGIX to the extent that such activities involve a Licensed Patent or Joint Patent. AGIX shall identify any such Prosecution activity to the IPC and provide the IPC copies of any official action, filing (including a draft patent application), communication, proposed submission in response to, and associated data or information, in a timely manner but in no case less than fourteen (14) days prior to the date any response to such official action or said application is proposed to be filed. AGIX and its patent counsel will reasonably consider AstraZeneca's comments thereon. If AstraZeneca does not provide AGIX with timely comments, AGIX shall be free to proceed with its submission or other contemplated action consistent with the direction of the IPC. (ii) For any pending patent applications within the Licensed Patents or any new patent applications that would otherwise be included in the Licensed Patents that the IPC believes should be filed, AGIX shall file and Prosecute patent applications or, if in the IPC's judgment the filing or prosecution of such applications would materially adversely affect any Licensed Patents, claims within patent applications, that in either case claim or are directed solely to the Compound or Product, or the Development, Manufacturing, formulation or use thereof. Any Prosecution activity in such patent application shall be directed by the IPC, in accordance with Section 9.3(b)(i), and implemented by AGIX in a manner consistent with Section 9.2(c)(ii).
View Source
Prosecution Activities. As between the Parties, and in accordance with Section 6.2.5, Syros shall have the first right, but not the obligation, to be the Prosecuting Party for the Validated Target Patents, worldwide, at Incyte’s sole cost and expense and using counsel mutually agreed upon by the Parties. If Syros decides that it will not conduct, or will cease to conduct, the Prosecution Activities with respect to any Validated Target Patent, in any country, then, subject to Incyte fulfilling its obligations with respect to such costs and expenses, Syros shall provide written notice to Incyte of such intention at least [**] in advance of any deadline for avoiding abandonment of (or other loss of rights with respect to) such Validated Target Patent, and Incyte shall thereupon have the option, in its sole discretion and in accordance with Section 6.2.5, to become the Prosecuting Party for such Validated Target Patent in such country, at Incyte’s sole cost and expense and using counsel mutually agreed upon by the Parties.
View Source
Prosecution Activities. AstraZeneca shall control Prosecution of all AstraZeneca Patents, at its sole expense; provided, however, that AstraZeneca shall reasonably consider AGIX's comments thereon. AstraZeneca shall identify any such Prosecution activity to the IPC and provide the IPC copies of any official action, filing (including a draft patent application), communication, proposed submission in response to, and associated data or information, in a timely manner but in no case less than fourteen (14) days prior to the date any response to such official action or said application is proposed to be filed. AstraZeneca and its patent counsel will reasonably consider AGIX's comments thereon; provided, however, that resolution of any issue under this Section 9.3(c) shall be decided by AstraZeneca in its discretion.
View Source
Prosecution Activities. (i) With respect to a given Licensed Patent, the Prosecuting Party with respect thereto shall, unless and until such Party informs the other Party that it elects not to pursue or continue the Prosecution of a Licensed Patent in a given country: (A) file and prosecute Patent applications to secure Patent rights for such Licensed Patent [***] in the [***] and [***] and such other countries as mutually agreed by AstraZeneca and Nektar (and such other countries as such Prosecuting Party elects); and (B) consult with the other Party (through its representatives on the Patent Working Group) regarding such Prosecution efforts (to the extent required by subsection (a) above), by providing such other Party a reasonable opportunity to review and participate in such Prosecution efforts regarding the applicable Patent Rights, including by providing to the Patent Working Group copies of all material communications from any patent authority in the Territory regarding such patent applications, and by providing drafts of any responses and any material filings to be made to such patent authorities reasonably in advance of submitting such responses or filings, and reasonably discussing any comments made by the other Party regarding such Prosecution efforts and in good faith seeking to accommodate all reasonable comments made by the other Party, and (C) upon issuance, maintain such Licensed Patent [***]. (ii) [***].
View Source

Related to Prosecution Activities

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Prosecution Hospital shall be responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents included in Patent Rights. Company shall reimburse Hospital for Patent Costs incurred by Hospital relating thereto in accordance with Section 4.2.

  • Prosecution of Work The execution of this Agreement shall constitute Consultant's authority to proceed immediately with the performance of this Agreement. Performance of the services hereunder shall be completed within the time required herein, provided, however, that if the performance is delayed by earthquake, flood, high water, or other Act of God or by strike, lockout, or similar labor disturbances, the time for Consultant's performance of this Agreement shall be extended by a number of days equal to the number of days Consultant has been delayed.

  • Patent Prosecution 6.1 UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement the PATENT RIGHTS in the United States and in such foreign countries as may be designated by LICENSEE in a written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. LICENSEE shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a “Small Entity” as provided by the United States Patent and Trademark Office. 6.2 All fees and costs including attorneys’ fees relating to the filing, prosecution and maintenance of the PATENT RIGHTS whether incurred prior to or after the EFFECTIVE DATE of this Agreement shall be the responsibility of LICENSEE. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs shall be paid by LICENSEE within thirty (30) days after receipt of UNIVERSITY’S invoice therefore. Payments pursuant to this Section 6.2 are not creditable against royalties. 6.3 LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the SLE FIELD developed independently of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY any fee or royalty under section 4 relating to such a new patent application, and any patent that issues therefrom, or new technology.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.